Heart Failure (HFpEF)
Heart failure with preserved ejection fraction
What it is
HFpEF is heart failure in which the heart's squeezing function (ejection fraction) is preserved, but the heart is stiff and fills poorly — causing breathlessness, fatigue, and fluid retention. It is now about half of all heart failure and is strongly tied to aging, obesity, hypertension, and diabetes.
Why it matters
HFpEF was long considered hard to treat, but that has changed: it is a highly metabolic, cardiometabolic disease, and SGLT2 inhibitors are now proven to reduce its hospitalizations. Recognizing it — and its drivers — opens real, evidence-based treatment.
What BioSignal knows about treating this
What works for Heart Failure (HFpEF)
BioSignal’s clinical summary, most important first.
- SGLT2 inhibitors (proven to reduce hospitalizations)
- Weight loss (including GLP-1 therapy in obesity-related HFpEF)
- Blood pressure control
- Diuretics for congestion
- Exercise and cardiac rehabilitation
Signal Records relevant to this condition
Interventions and contributing factors — some of these records describe a cause rather than a cure. The rating shown is BioSignal’s confidence in that Signal Record, not a claim about how well it treats this condition. Open any of them for the full evidence.
- Coenzyme Q10 (CoQ10)Limited evidence
Doesn't fix statin muscle aches — the trials tested that and it failed. The real open question is heart failure, where one randomised trial reported fewer deaths.
- SGLT2 InhibitorsHigh confidence
Modest glucose lowering but proven heart-failure and kidney protection, even without diabetes; manageable risks.
- AnticoagulantsHigh confidence
Among the most effective drugs in medicine — roughly a two-thirds reduction in AF stroke. The complexity is not whether they work; it is which one, for whom, and what else you are taking.
New to this? Read these first
How this usually unfolds
- Recognize risk factors
- Get diagnosed
- Track key biomarkers
- Lifestyle first
- Evidence-based treatment
- Long-term monitoring
Who is at risk
- Older age
- Obesity
- Hypertension
- Type 2 diabetes
- Chronic kidney disease
- Atrial fibrillation
How it's diagnosed
Suspected from symptoms plus a preserved ejection fraction on echocardiography, evidence of raised filling pressures (e.g., diastolic dysfunction, elevated natriuretic peptides), and supportive scores. Other causes of breathlessness are excluded.
Key biomarkers
Lifestyle
Explore this condition across BioSignal
Related Foundations
Related Signal Records
Related peptide families
Related body systems
Frequently asked questions
Is HFpEF treatable?
Yes — more than it used to be. SGLT2 inhibitors reduce hospitalizations, weight loss helps (especially in obesity-related HFpEF), and controlling blood pressure and the metabolic drivers matters. It's a cardiometabolic disease with real levers.
How is it different from other heart failure?
In HFpEF the heart still squeezes normally but is stiff and fills poorly, whereas in reduced-ejection-fraction heart failure the squeeze itself is weak. The treatments overlap but differ.
Evidence summary
SGLT2 inhibitors have randomized evidence for reducing HFpEF hospitalizations, and weight loss (including GLP-1 therapy) has trial support in obesity-related HFpEF; the metabolic drivers of HFpEF are well established.
References & sources
- SGLT2 heart-failure trials (EMPEROR-Preserved, DELIVER)
- STEP-HFpEF (semaglutide)
- ACC/AHA/HFSA Heart Failure Guideline
Educational information — not medical advice
Is this condition page clear, accurate, and useful? Your feedback shapes what we review next.
Give feedback